Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Nitrous oxide
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
===Anxiolytic effect=== In behavioural tests of [[anxiety]], a low dose of {{chem|N|2|O}} is an effective [[anxiolytic]]. This anti-anxiety effect is associated with enhanced activity of GABA{{ssub|A}} receptors, as it is partially reversed by [[GABAA receptor|benzodiazepine receptor]] [[receptor antagonist|antagonists]]. Mirroring this, animals that have developed tolerance to the anxiolytic effects of [[benzodiazepine]]s are partially tolerant to {{chem|N|2|O}}.<ref name="emmanouil">{{cite journal|title=Nitrous oxide anxiolytic effect in mice in the elevated plus maze: mediation by benzodiazepine receptors |vauthors=Emmanouil DE, Johnson CH, Quock RM |journal=Psychopharmacology |volume=115 |issue=1β2 |pages=167β72 |year=1994 |doi=10.1007/BF02244768 |pmid=7862891|s2cid=21652496 }}</ref> Indeed, in humans given 30% {{chem|N|2|O}}, benzodiazepine receptor antagonists reduced the subjective reports of feeling "high", but did not alter [[psychomotor learning|psychomotor]] performance.<ref name="zacny">{{cite journal|title=Flumazenil may attenuate some subjective effects of nitrous oxide in humans: a preliminary report |vauthors=Zacny JP, Yajnik S, Coalson D, Lichtor JL, Apfelbaum JL, Rupani G, Young C, Thapar P, Klafta J |journal=Pharmacology Biochemistry and Behavior |volume=51 |issue=4 |pages=815β9 |year=1995 |doi=10.1016/0091-3057(95)00039-Y |pmid=7675863|s2cid=39068081 }}</ref><ref>{{Cite journal |last=Gillman |first=Mark Akfred |date=2022 |title=What is better for psychiatry: Titrated or fixed concentrations of nitrous oxide? |journal=Front. Psychiatry |volume=13 |issue=773190 |pages=460β3|doi=10.3389/fpsyt.2022.773190 |pmid=36072452 |pmc=9441863 |doi-access=free }}</ref>
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)